ITM to supply Advanced Accelerator Applications on an industrial scale with its high-quality n.c.a. lutetium-177 as core component of the newly approved radiotherapeutic, PluvictoTM ITM Isotope
FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2.
The agency has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for treatment and gallium Ga 68 gozetotide (Locametz) as a diagnostic for use with PET imaging.
Ad hoc announcement pursuant to Art. 53 LR FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68.
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer